Nonclinical precedent Request an invite

Vabysmo: genotox, carcinogenicity and repro: done or skipped?

faricimab · VEGF-A x Ang-2
Genotoxicity
Not conducted (ICH S6(R1))
“In accordance with ICH S6(R1) guidance, standard genotoxicity studies were not conducted with faricimab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Carcinogenicity
Not conducted (no rodent VEGF-A binding); weight-of-evidence carcinogenicity assessment document
“No standard rodent carcinogenicity studies have been conducted as faricimab showed no relevant binding to mouse or rat VEGF-A.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Monkey EFD (IV, GD20-48): non-dose-dependent increase in abortions, no NOAEL; fertility via 6-month study organ histology
“An embryofetal development (EFD) study in cynomolgus monkeys showed an increase incidence of abortions in faricimab treated monkeys at IV doses of 1 or 3 mg/kg administered weekly on gestation days 20 to 48.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Safety pharmacology
No stand-alone studies; endpoints in 2-month and 6-month monkey tox studies
“Stand-alone safety pharmacology studies were not performed.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Genotox: Ames
Not conducted (ICH S6(R1))
“In accordance with ICH S6(R1) guidance, standard genotoxicity studies were not conducted with faricimab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Genotox: in vitro mammalian
Not conducted (ICH S6(R1))
“In accordance with ICH S6(R1) guidance, standard genotoxicity studies were not conducted with faricimab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Genotox: in vivo
Not conducted (ICH S6(R1))
“In accordance with ICH S6(R1) guidance, standard genotoxicity studies were not conducted with faricimab.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Carcinogenicity model
Not conducted; carcinogenicity assessment document (weight of evidence)
“No standard rodent carcinogenicity studies have been conducted as faricimab showed no relevant binding to mouse or rat VEGF-A.”
✓ VerifiedFDA pharmacology/toxicology review, p. 37Source ↗
Carcinogenicity timing
Not required; weight of evidence does not suggest carcinogenic potential
“No standard rodent carcinogenicity studies have been conducted as faricimab is not fully cross-reactive in rodents. The intended anti-angiogenic effects of faricimab and the weight of evidence do not suggest a carcinogenic potential of faricimab.”
✓ VerifiedEMA assessment report, p. 34Source ↗
hERG / QT
No hERG assay; monkey telemetry ECG incl. QT/QTc comparable to controls
“In both studies, heart rate and ECG endpoints, including QT and QTc, were comparable between control and faricimab-dosed groups.”
✓ VerifiedEMA assessment report, p. 34Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Not conducted (ICH S6(R1))

Blincyto

blinatumomab · CD19 x CD3
Not conducted (ICH S6(R1); protein of natural amino acids)

Columvi

glofitamab · CD20 x CD3
Not conducted (ICH S6(R1))

Elrexfio

elranatamab · BCMA x CD3
Not conducted (ICH S6(R1))

Epkinly

epcoritamab · CD20 x CD3
Not conducted (ICH S6(R1), ICH S9)

Hemlibra

emicizumab · FIXa x FX
Not conducted (ICH S6)

Imdelltra

tarlatamab · DLL3 x CD3
Not conducted (ICH S6(R1))

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
Not conducted (fusion protein; ICH S6/S9)

Korjuny

catumaxomab · EpCAM x CD3
Not conducted (ICH S6(R1))

Lunsumio

mosunetuzumab · CD20 x CD3
Not conducted (ICH S6(R1))

Lynozyfic

linvoseltamab · BCMA x CD3
Not conducted (antibody not expected to interact with DNA)

Ordspono

odronextamab · CD20 x CD3
Not conducted (antibody not expected to interact with DNA)

Removab

catumaxomab · EpCAM x CD3
Not conducted (not submitted; biologic, no relevant model)

Rybrevant

amivantamab · EGFR x MET
Not conducted (not appropriate for antibodies)

Talvey

talquetamab · GPRC5D x CD3
Not conducted (ICH S6; biotechnology-derived product)

Tecvayli

teclistamab · BCMA x CD3
Not conducted (ICH S6(R1))

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Not conducted (ICH S6(R1), ICH S9)

Summary across all 18 multispecifics →